Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Theratechnologies Inc
T.TH
Alternate Symbol(s):
THTX
Healthcare
Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs...
in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
TSX:TH - Post Discussion
Theratechnologies Inc
> Breast cancer
New Post
View:
Discussion
List
(212)
•••
scarlet1967
X
View Profile
View Bullboard History
Post by
scarlet1967
on Feb 03, 2021 12:26pm
Breast cancer
Spartrap just posted this research study from university of Gothenburg in Sweden published recently.
Read page 40!
https://gupea.ub.gu.se/bitstream/2077/66821/2/gupea_2077_66821_2.pdf
(212)
•••
scarlet1967
X
View Profile
View Bullboard History
Comment by
scarlet1967
on Feb 03, 2021 12:27pm
https://stocktwits.com/Spartrap/message/283183986
(258)
•••
qwerty22
X
View Profile
View Bullboard History
Comment by
qwerty22
on Feb 03, 2021 12:52pm
It really doesn't take much to show if THTX's drug has an inhibitory effect of this progranulin/sortilin mechanism. Basically all you need to do is repeat the expt the Swede's did but replace the sortilin inhibitor with THTTX's drug and see if you get the same outcome, maybe throw in a few more controls as well like THTX's peptide-alone and docetaxel-alone but you get an answer
...more
(212)
•••
scarlet1967
X
View Profile
View Bullboard History
Comment by
scarlet1967
on Feb 03, 2021 1:09pm
“Progranulin and one of its signaling receptors sortilin have previously been shown to be involved in cancer stem cell propagation and in metastasis formation. Taken together, these results demonstrated that progranulin increased cell secretion of many proteins, several of them dependent on sortilin binding. It has previously been shown that progranulin increase metastasis formation via sortilin
...more
(258)
•••
qwerty22
X
View Profile
View Bullboard History
Comment by
qwerty22
on Feb 03, 2021 2:03pm
It's proving the drug actually interferes with that process is what is required.
(212)
•••
scarlet1967
X
View Profile
View Bullboard History
Comment by
scarlet1967
on Feb 03, 2021 2:09pm
Yes I sent it to Leah...
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Do you want to stay ahead of the markets? See how DealRoom can help.
Debt-Free Cannabis Company Set for Next Stage of Growth
Growth Rocket 2025 – Why dynaCERT is in the Spotlight
Learn How this Company is Disrupting Point-of-Care Testing
Why Dozens of Pro Athletes are Paying Attention to this Product